Literature DB >> 10773084

Methylation mosaicism of 5'-(CGG)(n)-3' repeats in fragile X, premutation and normal individuals.

B Genç1, H Müller-Hartmann, M Zeschnigk, H Deissler, B Schmitz, F Majewski, A von Gontard, W Doerfler.   

Abstract

Fragile X syndrome (FRAXA) is characterized at the molecular level by an expansion of a naturally occurring 5'-(CGG)(n)-3' repeat in the promoter and 5'-untranslated region (5'-UTR) of the fragile X mental retardation (FMR1) gene on human chromosome Xq27.3. When expanded, this region is usually hypermethylated. Inactivation of the FMR1 promoter and absence of the FMR1 protein are the likely cause of the syndrome. By using the bisulfite protocol of the genomic sequencing method, we have determined the methylation patterns in this region on single chromosomes of healthy individuals and of selected premutation carriers and FRAXA patients. In control experiments with unmethylated or M- Sss I-premethylated DNAs, this protocol has been ascertained to reliably detect all cytidines or 5-methylcytidines as unmethylated or methylated nucleotides, respectively. Analyses of the DNA from FRAXA patients reveal considerable variability in the lengths of the 5'-(CGG)(n)-3' repeats and in the levels of methylation in the repeat and the 5'-UTR. In one patient (OEl) with high repeat length hetero-geneity ( n = 15 to >200), shorter repeats (n = 20-80) were methylated or unmethylated, longer repeats ( n = 100-150) were often completely methylated, but one repeat with n = 160 proved to be completely unmethylated. This type of methylation mosaicism was observed in several FRAXA patients. In healthy females, methylated 5'-CG-3' sequences were found in some repeats and 5'-UTRs, as expected for the sequences from one of the X chromosomes. The natural FMR1 promoter is methylation sensitive, as demonstrated by the loss of activity in transfection experiments using the unmethylated or M- Sss I-premethylated FMR1 promoter fused to the luciferase gene as an activity indicator.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10773084      PMCID: PMC105369          DOI: 10.1093/nar/28.10.2141

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  41 in total

1.  A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands.

Authors:  M Frommer; L E McDonald; D S Millar; C M Collis; F Watt; G W Grigg; P L Molloy; C L Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

2.  Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome.

Authors:  I Oberlé; F Rousseau; D Heitz; C Kretz; D Devys; A Hanauer; J Boué; M F Bertheas; J L Mandel
Journal:  Science       Date:  1991-05-24       Impact factor: 47.728

Review 3.  Patterns of DNA methylation--evolutionary vestiges of foreign DNA inactivation as a host defense mechanism. A proposal.

Authors:  W Doerfler
Journal:  Biol Chem Hoppe Seyler       Date:  1991-08

4.  In vitro DNA methylation inhibits FMR-1 promoter.

Authors:  W L Hwu; Y M Lee; S C Lee; T R Wang
Journal:  Biochem Biophys Res Commun       Date:  1993-05-28       Impact factor: 3.575

5.  A rapid optimized protocol for downward alkaline Southern blotting of DNA.

Authors:  P A Koetsier; J Schorr; W Doerfler
Journal:  Biotechniques       Date:  1993-08       Impact factor: 1.993

6.  On some technical aspects of direct DNA diagnosis of the fragile X syndrome.

Authors:  F Rousseau; D Heitz; V Biancalana; I Oberlé; J L Mandel
Journal:  Am J Med Genet       Date:  1992 Apr 15-May 1

7.  Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox.

Authors:  Y H Fu; D P Kuhl; A Pizzuti; M Pieretti; J S Sutcliffe; S Richards; A J Verkerk; J J Holden; R G Fenwick; S T Warren
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

8.  Absence of expression of the FMR-1 gene in fragile X syndrome.

Authors:  M Pieretti; F P Zhang; Y H Fu; S T Warren; B A Oostra; C T Caskey; D L Nelson
Journal:  Cell       Date:  1991-08-23       Impact factor: 41.582

9.  Methylation analysis of CGG sites in the CpG island of the human FMR1 gene.

Authors:  R S Hansen; S M Gartler; C R Scott; S H Chen; C D Laird
Journal:  Hum Mol Genet       Date:  1992-11       Impact factor: 6.150

10.  Studies on transformation of Escherichia coli with plasmids.

Authors:  D Hanahan
Journal:  J Mol Biol       Date:  1983-06-05       Impact factor: 5.469

View more
  14 in total

1.  CpG methylation modifies the genetic stability of cloned repeat sequences.

Authors:  Kerrie Nichol; Christopher E Pearson
Journal:  Genome Res       Date:  2002-08       Impact factor: 9.043

2.  FMR1 gene mutations in patients with fragile X syndrome and obligate carriers: 30 years of experience in Chile.

Authors:  Lorena Santa María; Solange Aliaga; Víctor Faundes; Paulina Morales; Ángela Pugin; Bianca Curotto; Paula Soto; M Ignacia Peña; Isabel Salas; M Angélica Alliende
Journal:  Genet Res (Camb)       Date:  2016-06-28       Impact factor: 1.588

3.  A distinct DNA-methylation boundary in the 5'- upstream sequence of the FMR1 promoter binds nuclear proteins and is lost in fragile X syndrome.

Authors:  Anja Naumann; Norbert Hochstein; Stefanie Weber; Ellen Fanning; Walter Doerfler
Journal:  Am J Hum Genet       Date:  2009-10-22       Impact factor: 11.025

4.  Size and methylation mosaicism in males with Fragile X syndrome.

Authors:  Poonnada Jiraanont; Madhur Kumar; Hiu-Tung Tang; Glenda Espinal; Paul J Hagerman; Randi J Hagerman; Nuanchan Chutabhakdikul; Flora Tassone
Journal:  Expert Rev Mol Diagn       Date:  2017-11       Impact factor: 5.225

Review 5.  Pharmacotherapy for Fragile X Syndrome: Progress to Date.

Authors:  Matthew H Davenport; Tori L Schaefer; Katherine J Friedmann; Sarah E Fitzpatrick; Craig A Erickson
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546

6.  An origin of DNA replication in the promoter region of the human fragile X mental retardation (FMR1) gene.

Authors:  Steven J Gray; Jeannine Gerhardt; Walter Doerfler; Lawrence E Small; Ellen Fanning
Journal:  Mol Cell Biol       Date:  2006-11-13       Impact factor: 4.272

7.  Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMR1 gene in fragile X cells treated with 5-azadeoxycytidine.

Authors:  Roberta Pietrobono; Maria Grazia Pomponi; Elisabetta Tabolacci; Ben Oostra; Pietro Chiurazzi; Giovanni Neri
Journal:  Nucleic Acids Res       Date:  2002-07-15       Impact factor: 16.971

Review 8.  Instability and chromatin structure of expanded trinucleotide repeats.

Authors:  Vincent Dion; John H Wilson
Journal:  Trends Genet       Date:  2009-06-18       Impact factor: 11.639

Review 9.  Mechanism of repeat-associated microRNAs in fragile X syndrome.

Authors:  Karen Kelley; Shin-Ju E Chang; Shi-Lung Lin
Journal:  Neural Plast       Date:  2012-06-20       Impact factor: 3.599

10.  Methyl-CpG-binding PCR of bloodspots for confirmation of fragile X syndrome in males.

Authors:  Ching-Cherng Tzeng; Chiou-Ping Liou; Chien-Feng Li; Ming-Chi Lai; Li-Ping Tsai; Wei-Chen Cho; Hui-Ting Chang
Journal:  J Biomed Biotechnol       Date:  2009-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.